Myriad Genetics treatment shows improvement in depression

Myriad Genetics’ wholly-owned subsidiary Assurex Health announced results from the Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment study highlighted at the 2018 ASCP annual meeting in Miami Beach. The key finding is that patients with depression whose medication selection was guided by the GeneSight Psychotropic genetic test saw improvements in remission, response and symptoms when treated by both primary care physicians and psychiatrists. Additionally, patients treated by primary care physicians exhibited 33% more symptom improvement, 34% increased response and 57% greater remission than those treated by psychiatrists. This study evaluated the clinical utility of the GeneSight test in selecting medications for 2,025 patients with moderate-to-severe major depressive disorder who were enrolled in the IMPACT study. Patients saw a 28% mean reduction in symptoms. Additionally, 26% of patients responded to treatment and 17% achieved remission, which is consistent with previously reported studies

https://bit.ly/2J4NXNe